Loading company…
T-CURX develops personalized CAR-T cell therapies for cancer.
T-CURX develops engineered CAR-T cells for hematological cancers and solid tumors, using non-viral genetic modification and a modular CAR format. Founded in 2017, the company is based in Wurzburg, Germany. In December 2025, it raised EUR 17.7 million in Series A funding led by BioMed Partners, with Bayern Kapital, WuXi Biologics (Cayman) Inc., HighLight Capital and i&i Bio participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in